Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
36.25
+0.45 (1.26%)
At close: Nov 8, 2024, 4:00 PM
36.01
-0.24 (-0.66%)
After-hours: Nov 8, 2024, 5:04 PM EST
Exelixis Employees
Exelixis had 1,310 employees as of December 31, 2023. The number of employees increased by 87 or 7.11% compared to the previous year.
Employees
1,310
Change (1Y)
87
Growth (1Y)
7.11%
Revenue / Employee
$1,589,006
Profits / Employee
$356,431
Market Cap
10.35B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,310 | 87 | 7.11% |
Dec 31, 2022 | 1,223 | 269 | 28.20% |
Dec 31, 2021 | 954 | 181 | 23.42% |
Dec 31, 2020 | 773 | 156 | 25.28% |
Dec 31, 2019 | 617 | 133 | 27.48% |
Dec 31, 2018 | 484 | 112 | 30.11% |
Dec 31, 2017 | 372 | 85 | 29.62% |
Dec 31, 2016 | 287 | 172 | 149.57% |
Dec 31, 2015 | 115 | 17 | 17.35% |
Dec 31, 2014 | 98 | -129 | -56.83% |
Dec 31, 2013 | 227 | 53 | 30.46% |
Dec 31, 2012 | 174 | -26 | -13.00% |
Dec 31, 2011 | 200 | -183 | -47.78% |
Dec 31, 2010 | 383 | -293 | -43.34% |
Dec 31, 2009 | 676 | 0 | - |
Dec 31, 2008 | 676 | -59 | -8.03% |
Dec 31, 2007 | 735 | 84 | 12.90% |
Dec 31, 2006 | 651 | 101 | 18.36% |
Dec 31, 2005 | 550 | 33 | 6.38% |
Dec 31, 2004 | 517 | -56 | -9.77% |
Dec 31, 2003 | 573 | 23 | 4.18% |
Dec 31, 2002 | 550 | -21 | -3.68% |
Dec 31, 2001 | 571 | 214 | 59.94% |
Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Encompass Health | 37,761 |
Charles River Laboratories International | 21,800 |
Smith & Nephew | 19,081 |
Catalent | 17,800 |
Bio-Rad Laboratories | 8,030 |
Bio-Rad Laboratories | 8,030 |
Qiagen | 5,967 |
Globus Medical | 5,000 |
EXEL News
- 2 days ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - Business Wire
- 10 days ago - Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
- 11 days ago - Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 19 days ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha
- 23 days ago - Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials - Seeking Alpha
- 25 days ago - Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 - Business Wire
- 26 days ago - Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories - Business Wire